Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura

Abstract

In this study, we examined changes in the plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tissue-type plasminogen activator (tPA)/PAI-I complex in patients with disseminated intravascular coagulation (DIC) and in those with thrombotic thrombocytopenic purpura (TTP) to investigate the fibrinolytic function and its relation to organ failure, The plasma levels of total PAI-I and tPA/PAI-I complex were significantly higher in patients with DIC, pre-DIC, and TTP than in those with non-DIC. The plasma levels of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer, thrombomodulin (TM), total PAI-I, and tPA/PAI-I complex were significantly higher in patients with organ failure than in those without organ failure. The plasma levels of total PAI-I and tPA/PAI-I complex were markedly increased in patients with acute leukemia. The plasma levels of total PAI-1, but not those of tPA/PAI-I complex, were significantly increased in patients with sepsis or with solid cancer. In all cases, total PAI-I or tPA/PAI-I complex was not significantly correlated with any hemostatic marker. Measurement of total PAI-I and tPA/PAI-I complex may be useful in the diagnosis of DIC.

Keywords

Plasminogen activator inhibitor-I tPA/PAI-I complex DIC TTP.

References

Sprengers ED , Kluft C. Plasminogen activator inhibitor . Blood 1987:69:381.

Chmielewska J. , Ranby M. Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31: 427.

Kruithof Eko , Tran TC , Ransijn A. , et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984;64:907.

Johan VI , Moreman B. , DeCock F. , et al. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984;33:523.

Heckman CM , Loskutoff DJ Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985;260:581.

Kruithor Eko , Tran-Thang C. , Ransijn A. , et al. Demonstration of a fast acting inhibitor of plasminogen activators in human plasma. Blood 1984;64:907.

Chander WL , Trimble SL , Loo SC , et al. Effect of PAI-I levels on the molar concentrations of active, tissue plasminogen activator (t-PA) and t-PA/PAI-I complex in plasma. Blood 1990;76:930.

Alessi MC , Juhan-Vague I. , Declerck PJ , et al, Correlations between t-PA and PAI-I antigen and activity and t-PA/PAI-I complex in plasma of control subjects and of patients with increased t-PA or PAI-I levels. Thromb Res 1990:60:509.

Kidokoro A. , Iba T. , Fukanaga M. , et al. Alterations in coagulation and fibrinolysis during sepsis. Shock 1996;5:223.

10.

Bukouski RM Thrombotic thrombocytopenic purpura. A review . Prog Hemost Thromb 1982;6:287.

11.

Ammorosi EL , Ultmann JE Thrombotic thrombocytopenic purpura: Report of the 16 cases and review of the literature. Medicine 1966;45:139.

12.

Kelton JG , Moore J. , Santos A. , et al. Detection of a platelet agglutinating factor in thrombotic thrombocytopenic purpura. Ann Intern Med 1984;101:589.

13.

Moake JL , Rudy CK , Troll JH , et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432.

14.

Wada H. Kaneko T. , Ohiwa M. , et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993 ;44:101.

15.

Wada H. , Kumeda Y. , Ogasawara Z. et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol 1993;42:166.

16.

Wada H. , Kumeda Y. , Ogasawara Z. , et al. Stimulation of tissue type plasminogen activator by leukemic cell homogenates. Blood Coag Fibrinol 1993 ; 4:591.

17.

Wada H. , Minamikawa K. , Wakita Y. , et al. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation, Am J Hematol 1993,44:85.

18.

Kobayashi N. , Maegawa T. Takada M. , et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 1987:49:265.

19.

Wada H. , Minamikawa K. , Wakita Y. , et al. Hemostatic study before onset of disseminated intravascular coagutation. Am J Hematol 1994;43:190;

20.

Sakata Y. , Mori K. , Kamitsubo Y. , et al. Analysis of plasminogen activator inhibitor-I; particularly in disseminated intravascular coagulation. Blood Vessels 1989;20:467.

21.

Sakata Y. , Murakami T. , Noro A. , et al. The specific activity of plasminogen activator-I in disseminated vascular coagulation with acute promyelacytic leukemia. Blood 1991;77:1949.

22.

Mumuro J. , Loskutoff DJ Binding of type I plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem 1989;264:5058.

23.

William AK , Elizabeth AD , Douglas PW , et al. Prognosis in acute organ-systems failure. Ann Surg 1985:202:685.

24.

Baue AE Multiple progressive or sequential systems failure. Arch Surg 1975:110:779.

25.

Pralog G. , Calandra T. , Glauser MP , et al. Plasminogen activator inhibitor I: A new prognostic marker in septic shock. Thromb Haemost 1989;61:459.

26.

Coluci M. , Paramo JA , Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985;75:818